Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
European Journal of Clinical Pharmacology · 2023
DOI: 10.1007/s00228-023-03572-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2023. Verfasst von Majdoleen Alalawneh und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. Hauptthemen laut MEDLINE: Obesity, Morbid, Atrial Fibrillation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar University.
Abstract (Originalsprache)
Purpose
To investigate real-world prescribing trends and clinical outcomes based on body mass index (BMI) categorization in patients who received rivaroxaban therapy.
Methods
This was a retrospective cohort study involving all patients who received rivaroxaban therapy across all Hamad Medical Corporation (HMC) hospitals from 2015 to 2020.
Results
The number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3%) in 2015 to 1342 (28.9%) in 2020 ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
- Clinical Pharmacy Services, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
- Pharmacy Department, Heart Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
- Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
- College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
- College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. aawaisu@qu.edu.qa.
Förderung
- Qatar University
Zitieren
APA
Alalawneh, M., Rachid, O., Abdallah, I., Mahfouz, A., Elewa, H., Danjuma, M. I., Mohamed, A. E., & Awaisu, A. (2023). Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-023-03572-7
Vancouver
Alalawneh M, Rachid O, Abdallah I, Mahfouz A, Elewa H, Danjuma MI, et al. Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data. European Journal of Clinical Pharmacology. 2023. doi:10.1007/s00228-023-03572-7
BibTeX
@article{Alalawneh2023,
author = {Alalawneh, Majdoleen and Rachid, Ousama and Abdallah, Ibtihal and Mahfouz, Ahmed and Elewa, Hazem and Danjuma, Mohammed Ibn-Mas'ud and Mohamed, Asmaa Ezzeldin and Awaisu, Ahmed},
title = {Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data},
journal = {European Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1007/s00228-023-03572-7}
}
EUVIMED